文献速递免疫规划传染病防控与疫情报告

肺炎球菌结合疫苗对成人3型肺炎球菌肺炎的保护效果:系统综述与汇总分析

Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysis.
PubMed 文献 · Vaccine · 2019-09-12

系统综述与汇总分析评估PCV13对成人3型肺炎球菌社区获得性肺炎的直接保护效果。共纳入2篇已发表研究和1篇会议摘要,均为≥65岁成人。汇总个体数据后,PCV13对3型住院CAP的疫苗有效性为52.5%(95%CI: 6.2-75.9%)。

要点

  • PCV13对≥65岁成人3型住院CAP的汇总VE为52.5%(95%CI: 6.2-75.9%)。
  • 排除未发表研究后结果相似,VE为53.6%(95%CI: 6.7-76.9%)。
  • 现有证据仅限三项研究,提示PCV13对3型CAP有直接保护。

核心结论

  • 现有证据虽仅限三项研究,但提示PCV13对≥65岁成人3型住院CAP提供直接保护。

研究设计与样本

  • 系统综述与汇总分析,纳入2篇已发表研究和1篇未发表会议摘要,均为≥65岁成人研究。

主要发现

  • 三项研究包括荷兰RCT、美国肯塔基州测试阴性设计病例对照研究和阿根廷测试阴性设计研究。
  • 汇总个体数据后,PCV13对3型住院CAP的VE为52.5%(95%CI: 6.2-75.9%)。
  • 排除未发表研究后,VE为53.6%(95%CI: 6.7-76.9%),未观察到异质性。

关键数值与推荐

  • PCV13对≥65岁成人3型住院CAP的汇总VE为52.5%(95%CI: 6.2-75.9%)。
  • 排除未发表研究后VE为53.6%(95%CI: 6.7-76.9%)。

临床怎么用

  • 可为≥65岁成人接种PCV13以预防3型肺炎球菌住院CAP提供证据支持。

局限性

  • 证据仅基于三项研究,其中一项尚未正式发表。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Serotype 3 pneumococcal disease has not substantially declined at the population level after the routine introduction of 13-valent pneumococcal conjugate vaccine (PCV13) into pediatric immunization programs across the globe. This epidemiological finding has generated debate regarding the effectiveness of PCV13 against serotype 3 disease. Evaluating PCV13 effectiveness against serotype 3 is especially critical in adults, where serotype 3 makes up an important amount of remaining pneumococcal disease. METHODS: We performed a systematic review of the published literature to assess the direct effectiveness of PCV13 against serotype 3 community-acquired pneumonia (CAP) among adults. We then estimated overall vaccine effectiveness (VE) using a pooled analysis of the individual-level, raw data. RESULTS: Two published studies met inclusion criteria. One was a randomized controlled trial conducted in the Netherlands and published in 2014. The other was a recently-published case-control study conducted in Louisville, Kentucky that used a test-negative design (TND). We also identified a third TND study conducted in Argentina that was recently presented as a conference abstract but is not yet published. All three studies were conducted in adults aged ≥65 years. PCV13 VE against serotype 3 hospitalized CAP was 52.5% (95%CI: 6.2-75.9%) from the pooled analysis of individual-level data from all three studies. Results were similar if the unpublished estimate was excluded (serotype 3 VE = 53.6% [95%CI: 6.7-76.9%]). No heterogeneity was observed. CONCLUSIONS: Currently-available evidence, although limited to three studies, suggests that PCV13 provides direct protection against serotype 3 hospitalized CAP in adults aged ≥65 years.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. McLaughlin JM, Jiang Q, Gessner BD, et al. Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysis. Vaccine. 2019. PMID: 31522807. doi:10.1016/j.vaccine.2019.08.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。